Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05182827
Other study ID # RECHMPL21_0502
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 11, 2022
Est. completion date July 2023

Study information

Verified date March 2022
Source University Hospital, Montpellier
Contact Emilie OLIE, MD PhD
Phone +33 4 67 33 85 81
Email e-olie@chu-montpellier.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Several elements suggest that suicidal vulnerability may be associated with an alteration in the perception of affective touch. On the one hand, anhedonia, characterized by a decrease in the pleasure felt, is strongly associated with suicidal ideation, independently of depression. However, the ability to feel pleasure is essential in the perception of affective touch. On the other hand, suicidal behaviors are associated with interpersonal difficulties, of which communication is an integral part, and communication is partly through touch. The investigators therefore wish to explore the perception of affective touch in suicidal behavior by using an affective tactile stimulation in 72 subjects with and without a history of suicide attempts (SA).


Description:

This study aims to compare the perceived hedonic nature of affective touch in euthymic subjects with a history of SA and euthymic subjects without a history of SA. The investigators also aim to : - compare the perceived hedonic nature of non-affective touch in this population; - compare the perceived intensity of affective touch; - compare the perceived intensity of non-affective touch; - study the association between decision making performance and perceived pleasantness of affective vs. non-affective touch; - study the association between plasma beta-endorphin levels and the perceived pleasantness of affective vs. non-affective touch; - study the effect of the tactile stimulation on the expression of opioidergic genes, by comparing the mRNA levels of 6 genes coding for opioidergic receptors and peptides before and after tactile stimulation; - investigate the association between tactile stimulation-related opioidergic gene expression variation and the perception of the pleasantness of affective versus non-affective touch. To do so, 72 euthymic women will be included and divided in two groups: 1) Euthymic patients with a lifetime history of major depressive episode and a history of suicidal behavior; 2) Euthymic patients with a lifetime history of a major depressive episode and no history of suicidal behavior. Participants will be subjected to tactile stimulation (affective and non-affective), following a clinical and neurospychological assessment. During the experimental touch, participants will be asked to evaluate the pleasantness of the touch and its intensity. In addition, blood samples will be taken before and after the stimulation. Participation will be done in one day or in two visits, up to 72 hours apart. The investigators expect: 1) subjects with a history of TS to have a decreased perceived pleasantness of affective touch compared to subjects without a history of TS; 2) the difference between the perceived pleasantness of affective versus non-affective touch to be smaller in patients with a history of TS; 3) decision making to be related to the hedonic nature of affective touch; 4) a change in the expression of opioidergic genes. This study will contribute to a better knowledge of the vulnerability to suicidal behaviors and to a better understanding of psychopathology in order to offer specific and more adapted prevention and management strategies.


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date July 2023
Est. primary completion date January 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Being a woman - Aged between 18 and 65 - Past major depressive episode according to the DSM-5 criteria - Currently euthymic (Montgomery-Asberg Depression rating Scale (MADRS) < 12 and Young Mania Rating Scale (YMRS) < 6) - Minimal psychotropic medication (as determined by the clinician) - Able to understand experimental procedures - Able to speak, read and understand French - Having given written informed consent - For suicide attempters only: Lifetime history of suicide attempt - For affective controls only: No lifetime history of suicide attempt Exclusion Criteria: - Lifetime diagnosis of schizoaffective disorder, schizophrenia or autism spectrum disorder - Severe alcohol or substance use disorder in the past 6 months - Current anorexia nervosa - Diagnosis of mental retardation or severe medical comorbidity that is unstable or could interfere with measures (HIV, diabetes, cancer, chronic inflammatory disease, neurological disorder, sensory or cognitive disability) - Injury, scar, irritation/dermatological lesion or tattoo on the left forearm - Pregnancy or breastfeeding - Being in exclusion period for another study - Not being affiliated to the French National Social Security System - Being deprived of freedom (by judicial or administrative decision) - Being protected by law (guardianship or curatorship) - Having reached 4500€ annual compensation for participating to clinical trials

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Tactile stimulation
The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation. It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated. To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed). Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation. This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness.

Locations

Country Name City State
France Montpellier University Hospital, France (CHU) Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pleasantness of the touch Perceived pleasantness of the tactile stimulation, assessed with a numeric scale ranging from -5 (very unpleasant) to +5 (very pleasant) at inclusion
Secondary Intensity of the touch Perceived intensity of the tactile stimulation, assessed with a 10 points Likert scale (low intensity to high intensity). at inclusion
Secondary Decision-making performance (Iowa Gambling Test) Decision-making performance using the IG index from the Iowa Gambling Test (difference between the number of safe and risky choices) at inclusion
Secondary Decision-making performance (Ultimatum Game) Decision-making performance using the UG index from the Ultimatum Game (difference between the number of rejections of unfair and fair offers) at inclusion
Secondary ß-endorphin levels Plasmatic levels of ß-endorphin at inclusion
Secondary Variation in the expression of opioidergic genes Variation in mRNA levels of 6 genes coding for opioidergic receptors and peptides (OPRM1 (µ), OPRK1 (?), OPRD1 (d) and pro-opio-melanocortin, pro-enkephalin, pro-dynomorphin), before and after tactile stimulation at inclusion
See also
  Status Clinical Trial Phase
Completed NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Completed NCT01944293 - Ketamine for Suicidality in Bipolar Depression Phase 1/Phase 2
Recruiting NCT01441505 - A Study of Ketamine as an Antidepressant Phase 2
Active, not recruiting NCT03487926 - Microglial Activation in Inflammatory Bowel Disease
Recruiting NCT04939649 - Ketamine as an Adjunctive Therapy for Major Depression (2) Phase 3
Recruiting NCT05028738 - Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety N/A
Recruiting NCT03646058 - Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode Phase 3
Completed NCT03735576 - Cognitive Behavioural Therapy for the Treatment of Late Life Depression N/A
Recruiting NCT04999553 - Left vs. Right Non-Inferiority Trial N/A
Completed NCT03716869 - Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder N/A
Recruiting NCT02824081 - Neuroinflammation, Serotonin, Impulsivity and Suicide N/A
Terminated NCT01099592 - Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression Phase 4
Completed NCT03752853 - Stress Systems and Psychotherapy in Depression N/A
Recruiting NCT04480918 - University of Iowa Interventional Psychiatry Service Patient Registry
Recruiting NCT04130958 - Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics N/A
Completed NCT03190772 - The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation N/A
Recruiting NCT04832750 - Depression-Reduction by Accelerated Personalized NeuroModulation and Its Effects on Sleep
Terminated NCT02839798 - NeoSync TMS Treatment for Bipolar I Depression Phase 2
Completed NCT00852592 - Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial Phase 3
Terminated NCT05063604 - Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression Phase 2